Endocyte's ABX Deal To Serve As Springboard For Radioligand Pipeline

 
• By Emily Hayes

Company gains worldwide rights to mid-stage therapy 177Lu-PSMA-617, which would compete with Bayer/Algeta's radiopharmaceutical Xofigo in metastatic castration-resistant prostate cancer.

businessman and businesswoman are shaking hands and exchanging folder after agreement was reached

More from Deals

More from Business